NCT01201304

Brief Summary

This study compares the relative efficacy of three methods of delivering interoceptive exposure for the reduction of elevated anxiety sensitivity. The interventions vary according to their intensity and use of coping strategies during exposure. An expressive writing intervention serves as an expectancy control.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
120

participants targeted

Target at P50-P75 for phase_2

Timeline
Completed

Started Jan 2010

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2010

Completed
8 months until next milestone

First Submitted

Initial submission to the registry

September 9, 2010

Completed
5 days until next milestone

First Posted

Study publicly available on registry

September 14, 2010

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2012

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2012

Completed
Last Updated

January 31, 2012

Status Verified

January 1, 2012

Enrollment Period

2.2 years

First QC Date

September 9, 2010

Last Update Submit

January 26, 2012

Conditions

Keywords

Anxiety sensitivityPanic

Outcome Measures

Primary Outcomes (2)

  • Fear of Anxiety-Related Body Sensations

    Anxiety Sensitivity Index - Revised Concerns Subscale (12 items)

    Immediately following the single-session intervention

  • Fear of Anxiety-Related Body Sensations

    Anxiety Sensitivity Revised - Respiratory Concerns Subscale (12 items)

    One week after single-session intervention

Secondary Outcomes (4)

  • Hypervigilance to anxiety-related body sensations

    One week after the single-session intervention

  • Beck Anxiety Inventory

    One week after the single-session intervention

  • Peak Anxiety During a Symptom Induction Task

    Immediately following the single-session intervention

  • Peak Anxiety During a Symptom Induction Task

    One week after the single-session intervention

Study Arms (2)

Interoceptive exposure

EXPERIMENTAL

Repeated trials of voluntary hyperventilation intended to reduce fears of arousal-related body sensations.

Behavioral: Standard exposureBehavioral: Enhanced exposureBehavioral: Intensive exposure

Expressive writing

PLACEBO COMPARATOR

Expectancy control intervention.

Behavioral: Expressive writing

Interventions

Three 60-second trials of hyperventilation, each followed by diaphragmatic breathing, cognitive reappraisal, and prolonged rest until body sensations have subsided.

Interoceptive exposure

Three 60-second trials of hyperventilation, each followed by a 15-second rest period and cognitive reappraisal.

Interoceptive exposure

Minimum of eight 60-second hyperventilation trials, each followed by 15-second rest period and cognitive reappraisal. Trials continue until participants rate the probability that their most feared outcome will occur as less than 5% on a 0% to 100% scale.

Interoceptive exposure

Individuals randomized to the expressive writing control group will receive a rationale for why writing about emotional issues helps resolve the fear of body sensations. These participants will then be asked to spend the next 25 minutes writing about past emotional issues. Participant writings are confidential and will not be viewed by the experimenter.

Expressive writing

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Score \> 21 on Anxiety Sensitivity Index - Revised Fear of Respiratory Symptoms Subscale.

You may not qualify if:

  • Seizures
  • Hypertension
  • Heart problems
  • Pregnancy
  • Asthma
  • Other health conditions exacerbated by intense exercise.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Wyoming

Laramie, Wyoming, 82071, United States

Location

Study Officials

  • Brett Deacon, Ph.D.

    University of Wyoming

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor of Psychology

Study Record Dates

First Submitted

September 9, 2010

First Posted

September 14, 2010

Study Start

January 1, 2010

Primary Completion

April 1, 2012

Study Completion

April 1, 2012

Last Updated

January 31, 2012

Record last verified: 2012-01

Locations